Sotatercept (formerly known as ACE-011), a recombinant activin receptor type IIA (ActRIIA) ligand trap comprising the extracellular domain of the human ActRIIA and human immunoglobulin G, has positive effects on bone metabolism and hematopoiesis in newly diagnosed and relapsed MM patients [61] (Table 3). This evidence concerns the gene ACVR2A and Miyoshi myopathy.